Be the first to like this
One of the most important and complex patent cases has just come to an end.
The US Supreme Court, the highest court in the States, recently heard an extremely difficult biotech case: Assoc. for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398, June 13, 2013 (hereafter 'Op.'). It's ruling is expected to have broad implications, not only in the U.S. but worldwide. The central question is: whether human genes could be patented? Put in a simple way: how genes, the basis for hereditary traits in living organisms, could become a company’s intellectual property; and who owns the gene?